指南与共识自身免疫性与大疱性皮肤病皮肤肿瘤

欧洲皮肤病与性病学会(EADV)发起的副肿瘤性天疱疮/副肿瘤性自身免疫多器官综合征管理S2k指南

S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV).
指南 / 共识 · J Eur Acad Dermatol Venereol · 2023-03-25

该S2k指南由EADV自身免疫性大疱病工作组联合相关学科制定,总结副肿瘤性天疱疮/副肿瘤性自身免疫多器官综合征(PNP/PAMS)的临床特征、诊断与管理推荐。推荐包括组织病理与免疫病理检查、抗包斑蛋白抗体或大鼠膀胱上皮间接免疫荧光检测,以及系统激素和利妥昔单抗治疗。

要点

  • 慢性严重黏膜炎和多形性皮损是PNP/PAMS的线索性临床特征。
  • 诊断推荐组织病理及直接/间接免疫荧光、ELISA,有条件时行免疫印迹/免疫沉淀。
  • 抗包斑蛋白抗体或大鼠膀胱上皮间接免疫荧光结合抗体是诊断PNP/PAMS最特异的工具。

核心结论

  • 本指南是首个欧洲关于PNP/PAMS诊断与管理的指南。
  • 诊断标准和治疗推荐需进一步通过前瞻性研究验证。

研究设计与样本

  • 由欧洲皮肤病与性病学会(EADV)自身免疫性大疱病工作组发起,相关学科医师参与制定。
  • 推荐强度为S2k级别,基于证据和专家意见,并纳入工作组全体成员的同意程度。

主要发现

  • 慢性严重黏膜炎和多形性皮肤病变是PNP/PAMS的线索性临床特征。
  • PNP/PAMS通常与淋巴增殖性或血液系统恶性肿瘤相关,较少与实体恶性肿瘤相关。
  • 因严重感染和疾病相关并发症(如闭塞性细支气管炎)风险增加,PNP/PAMS死亡率升高。

关键数值与推荐

  • 推荐对疑似PNP/PAMS患者进行完整评估,包括组织病理学研究和免疫病理学检查(直接和间接免疫荧光、ELISA,以及有条件时的免疫印迹/免疫沉淀)。
  • 检测抗包斑蛋白抗体和/或间接免疫荧光中与大鼠膀胱上皮结合的循环抗体,是临床和病史特征相符患者中诊断PNP/PAMS最特异的工具。
  • 推荐系统激素最高1.5 mg/kg/天作为一线治疗选择。
  • 推荐利妥昔单抗用于继发于淋巴增殖性疾病的PNP/PAMS患者,也可考虑用于与实体肿瘤相关的PNP/PAMS病例。
  • 推荐包括肺科医师、眼科医师和肿瘤血液科医师的多学科方法以实现最佳管理。

临床怎么用

  • 对疑似PNP/PAMS患者应进行完整评估,包括组织病理学和免疫病理学检查。
  • 抗包斑蛋白抗体和/或大鼠膀胱上皮间接免疫荧光结合抗体可用于诊断PNP/PAMS。
  • 系统激素最高1.5 mg/kg/天可作为一线治疗选择。
  • 利妥昔单抗推荐用于继发于淋巴增殖性疾病的PNP/PAMS,也可考虑用于实体肿瘤相关病例。
  • 推荐多学科团队(肺科、眼科、肿瘤血液科)参与管理。

局限性

  • 诊断标准和治疗推荐需进一步通过前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paraneoplastic pemphigus (PNP), also called paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare autoimmune disease with mucocutaneous and multi-organ involvement. PNP/PAMS is typically associated with lymphoproliferative or haematological malignancies, and less frequently with solid malignancies. The mortality rate of PNP/PAMS is elevated owing to the increased risk of severe infections and disease-associated complications, such as bronchiolitis obliterans. OBJECTIVES: These guidelines summarize evidence-based and expert-based recommendations (S2k level) for the clinical characterization, diagnosis and management of PNP/PAMS. They have been initiated by the Task Force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology with the contribution of physicians from all relevant disciplines. The degree of consent among all task force members was included. RESULTS: Chronic severe mucositis and polymorphic skin lesions are clue clinical characteristics of PNP/PAMS. A complete assessment of the patient with suspected PNP/PAMS, requiring histopathological study and immunopathological investigations, including direct and indirect immunofluorescence, ELISA and, where available, immunoblotting/immunoprecipitation, is recommended to achieve a diagnosis of PNP/PAMS. Detection of anti-envoplakin antibodies and/or circulating antibodies binding to the rat bladder epithelium at indirect immunofluorescence is the most specific tool for the diagnosis of PNP/PAMS in a patient with compatible clinical and anamnestic features. Treatment of PNP/PAMS is highly challenging. Systemic steroids up to 1.5 mg/kg/day are recommended as first-line option. Rituximab is also recommended in patients with PNP/PAMS secondary to lymphoproliferative conditions but might also be considered in cases of PNP/PAMS associated with solid tumours. A multidisciplinary approach involving pneumologists, ophthalmologists and onco-haematologists is recommended for optimal management of the patients. CONCLUSIONS: These are the first European guidelines for the diagnosis and management of PNP/PAMS. Diagnostic criteria and therapeutic recommendations will require further validation by prospective studies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2023. PMID: 36965110. doi:10.1111/jdv.18931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。